SI-BONE, Inc. (NASDAQ:SIBN) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in SI-BONE, Inc. (NASDAQ:SIBN) by 3.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 924,044 shares of the company’s stock after purchasing an additional 30,005 shares during the quarter. Geode Capital Management LLC owned about 2.20% of SI-BONE worth $12,921,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in SIBN. FMR LLC increased its holdings in shares of SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company’s stock valued at $33,000 after purchasing an additional 1,198 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of SI-BONE in the second quarter valued at approximately $61,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of SI-BONE by 24.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock valued at $138,000 after purchasing an additional 2,108 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of SI-BONE by 9.0% in the second quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock valued at $141,000 after purchasing an additional 903 shares during the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of SI-BONE in the third quarter valued at approximately $144,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

Wall Street Analyst Weigh In

SIBN has been the subject of several analyst reports. Truist Financial increased their price objective on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of SI-BONE in a research report on Wednesday, November 20th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, SI-BONE has a consensus rating of “Buy” and an average price target of $23.00.

Insider Transactions at SI-BONE

In other news, insider Anthony J. Recupero sold 3,937 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $12.60, for a total transaction of $49,606.20. Following the completion of the transaction, the insider now directly owns 228,554 shares in the company, valued at $2,879,780.40. This trade represents a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Anshul Maheshwari sold 2,439 shares of SI-BONE stock in a transaction on Monday, November 18th. The shares were sold at an average price of $12.68, for a total value of $30,926.52. Following the completion of the transaction, the chief financial officer now owns 194,623 shares of the company’s stock, valued at approximately $2,467,819.64. This trade represents a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,679 shares of company stock worth $276,439 over the last ninety days. Company insiders own 3.90% of the company’s stock.

SI-BONE Trading Down 0.1 %

SIBN opened at $13.71 on Tuesday. SI-BONE, Inc. has a 52 week low of $11.70 and a 52 week high of $21.64. The business has a fifty day simple moving average of $13.46 and a 200-day simple moving average of $14.09. The firm has a market cap of $574.97 million, a P/E ratio of -14.90 and a beta of 1.20. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.